Tags : Multiple Myeloma

Biotech

Sanofi Signs ~$1B Agreement with Eureka & MSK for their

Shots: Eureka and MSK are eligible to receive up front and ~$1B as development, regulatory and sales milestone along with royalties on net sales. Sanofi gets exclusive rights to the GPRC5D binder for non-CAR use Eureka discovered the GPRC5D binding domain using its E-ALPHA Abs discovery platform, under its collaboration with MSK Additionally, targeting GPRC5D […]Read More

M&A

AbbVie Acquire TeneoOne and its TNB-383B for the Treatment of

Shots: AbbVie exercised its exclusive right to acquire TeneoOne and its TNB-383B based on an interim analysis of an ongoing P-I study that demonstrated ORR (79%), VGPR (63%), CR (29%) at doses ≥40 mg in the dose-escalation cohorts with a median follow-up time of 6.1 mos., m-DOR has not been reached In Feb’2019, AbbVie and […]Read More